All Stories

  1. At the Crossroads of Lineage: Secondary Malignancies After CAR-Based Immunotherapy
  2. Trends in the design of FDA registrational randomised clinical trials in haematology and oncology: a 20-year cohort study
  3. Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial
  4. Eliminating REMS for CAR T-Cell Therapies: An Opportunity to Improve Access
  5. Eliminating REMS for CAR T-Cell Therapies: An Opportunity to Improve Access
  6. Chimeric antigen receptor T‐cell therapy for high‐grade B‐cell lymphoma NOS
  7. SGLT2 inhibitors and cardiovascular outcomes in patients with multiple myeloma and concomitant type 2 diabetes mellitus
  8. Estimation of Benefit to Bispecific Antibodies in US Patients with Lymphoma and Multiple Myeloma
  9. Safety landscape of bispecific antibody therapy in non-Hodgkin lymphoma: a meta-analysis
  10. CD19-directed CART therapy for T-cell/histiocyte–rich large B-cell lymphoma
  11. IgG replacement in multiple myeloma
  12. Relationships Among Health Insurance Literacy, Financial Toxicity, and Sociodemographic Factors in Patients With Cancer
  13. Complicated regulatory decision-making following inconsistent trial results: the issue with ibrutinib for mantle cell lymphoma
  14. Measurable Residual Disease in Chronic Lymphocytic Leukemia: Current Understanding and Evolving Role in Clinical Practice
  15. Allogeneic Hematopoietic Stem Cell Transplant for Diffuse Large B-Cell Lymphoma: Evolving Role in the Era of CAR T-Cell Therapy
  16. Quality of the control arms in randomized trials of chronic lymphocytic leukemia enrolling in the USA: A systematic review
  17. Isolated CNS relapse of blastic plasmacytoid dendritic cell neoplasm
  18. Prediction of immunomodulatory drugs (IMiDs) sensitivity in myeloma via determination of baseline anti-oxidative stress capacity
  19. Primary Central Nervous System Lymphoma: Consensus, Controversies and Future Directions
  20. Change in 21‐gene Recurrence Score result after exposure to neo‐adjuvant endocrine therapy in patients with operable breast cancer
  21. Gone But Here
  22. Clinical features and cell of origin subtyping using gene expression profiling in HIV-negative patients with primary central nervous system lymphoma
  23. Hemostatic complications associated with ventricular assist devices
  24. Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration
  25. Hanging Up the Gloves
  26. Neutropenic diets to prevent cancer infections: updated systematic review and meta-analysis
  27. Germ Cell Tumors with Malignant Somatic Transformation: A Mayo Clinic Experience
  28. Erratum
  29. Outcome disparities in colorectal cancer: a SEER-based comparative analysis of racial subgroups
  30. ASO Author Reflections: Role of Contrast-Enhanced Spectral Mammography in the Assessment of Residual Breast Cancer After Neoadjuvant Systemic Therapy
  31. I Don’t Know
  32. Eliminating MRD — FDA approval of blinatumomab for B-ALL in complete remission
  33. Rituximab maintenance therapy for mantle cell lymphoma: A systematic review and meta-analysis
  34. Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections
  35. Activity Of Imatinib In Clonal Extramedullary Myeloid Neoplasms With Eosinophilia
  36. Breast MRI phenotype and background parenchymal enhancement may predict tumor response to neoadjuvant endocrine therapy
  37. Economic Impact of Oral Therapies for Chronic Lymphocytic Leukemia—the Burden of Novelty
  38. Rituximab Maintenance Therapy After First-Line Induction Chemoimmunotherapy for Follicular Lymphoma
  39. Adjuvant Antiangiogenic Agents in Post-nephrectomy Renal Cell Carcinoma: A Systematic Review and Meta-analysis
  40. Brentuximab Vedotin for Stage III or IV Hodgkin’s Lymphoma
  41. Necrobiotic xanthogranuloma: a 30-year single-center experience
  42. Contrast-Enhanced Spectral Mammography is Comparable to MRI in the Assessment of Residual Breast Cancer Following Neoadjuvant Systemic Therapy
  43. Nivolumab-associated bone marrow necrosis
  44. A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma
  45. Myeloid neoplasm with eosinophilia associated with isolated extramedullary FIP1L1 / PDGFRA rearrangement
  46. B-cell acute lymphoblastic leukemia with +der(1)t(1;19) (p13;p13.1) arising in the setting of CALR exon 9 mutated essential thrombocythemia
  47. Comprehensive genomic profiling in routine clinical practice leads to a low rate of benefit from genotype-directed therapy
  48. Cytomegalovirus reactivation is associated with a lower rate of early relapse in myeloid malignancies independent of in-vivo T cell depletion strategy
  49. Update on lung neuroendocrine tumors
  50. ERBB2 (HER2)Testing in Breast Cancer
  51. Radiation-induced breast cancer: the question of early breast cancer screening in Hodgkin's lymphoma survivors
  52. Unexpected Cardiac Masses
  53. Exploring the possibilities: airspace disease in the postallogeneic haematopoietic stem cell transplant period
  54. The Perils of Country Life: Human Monocytic Ehrlichiosis
  55. Maintaining sharp focus on a grainy film: miliary pattern in an elderly woman with acute respiratory failure
  56. Sudden cardiac arrest in a healthy young athlete
  57. Bilateral upper lobe opacification
  58. Diffuse unresolving pulmonary nodules in a patient with a history of cervical carcinoma
  59. A tick-borne illness unmasking asymptomatic Brugada syndrome
  60. Fatal Cytomegalovirus Disease after Combination Therapy with Corticosteroids and Rituximab for Granulomatosis with Polyangiitis
  61. Disseminated tuberculosis with tuberculous meningitis in an immunocompetent host
  62. Chronic rupture of the coronary sinus of Valsalva with pseudoaneurysm formation
  63. A cause to consider for chronic unresolving diarrhea
  64. Fulminant Wilson’s Disease Managed with Plasmapheresis as a Bridge to Liver Transplant
  65. Isolated neurocutaneous peripheral T cell lymphoma, NOS